1. Home
  2. BFRG vs APM Comparison

BFRG vs APM Comparison

Compare BFRG & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bullfrog AI Holdings Inc.

BFRG

Bullfrog AI Holdings Inc.

HOLD

Current Price

$0.69

Market Cap

6.9M

Sector

Technology

ML Signal

HOLD

Logo Aptorum Group Limited

APM

Aptorum Group Limited

HOLD

Current Price

$0.84

Market Cap

7.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BFRG
APM
Founded
2017
2010
Country
United States
United Kingdom
Employees
17
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9M
7.3M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
BFRG
APM
Price
$0.69
$0.84
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
280.3K
255.6K
Earning Date
05-12-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$0.65
52 Week High
$2.04
$4.47

Technical Indicators

Market Signals
Indicator
BFRG
APM
Relative Strength Index (RSI) 53.00 43.86
Support Level $0.65 $0.74
Resistance Level $0.82 $0.93
Average True Range (ATR) 0.07 0.16
MACD 0.01 -0.02
Stochastic Oscillator 77.88 3.81

Price Performance

Historical Comparison
BFRG
APM

About BFRG Bullfrog AI Holdings Inc.

Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.

About APM Aptorum Group Limited

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.

Share on Social Networks: